SOHO 2024
Advertisement
Retrospective analysis shows that AML treatment strategies are effective for patients with MDS or CMML with NPM1 mutations.
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
A study demonstrated favorable outcomes among high-risk patients with newly diagnosed MM who received HSCT consolidation.
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM.
Daratumumab-based induction therapy showed improved responses and comparable safety in newly diagnosed multiple myeloma.
Adding isatuximab to standard-of-care improved CR and MRD negativity rates in transplant-eligible, newly diagnosed MM.
Adverse events were common in patients with CML receiving first- or second-generation tyrosine kinase inhibitors.
Venetoclax plus ibrutinib was associated with lower rates of mortality and serious adverse events than the control regimens.
MDS-related gene mutations and number of mutations did not correlate with worse outcomes.
The one-year overall survival rate of 90%, and the MRD negativity rate was 94%.
Pacritinib demonstrated superiority to best available therapy for spleen volume reduction, total symptom score, and more.
Patients with splenomegaly are more likely to be referred for HSCT.
Selinexor plus ruxolitinib was well tolerated, reduced symptom burden, and led to spleen volume reduction.
One year of pacritinib treatment stabilized or improved thrombocytopenia and anemia in patients with myelofibrosis.
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
This real-world study characterized step-up dosing models for talquetamab in patients with multiple myeloma.
Talquetamab and pomalidomide induced rapid and deep responses in patients with relapsed or refractory multiple myeloma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.